

Letters to the Editor

RE: "DECREASED RISK OF CELIAC DISEASE IN PATIENTS WITH HELICOBACTER PYLORI COLONIZATION"

We read with interest the study by Lebwohl et al. (1) suggesting that colonization with *Helicobacter pylori* may be protective against the development of celiac disease (CD). The authors present a well-conducted study demonstrating a 4.4% prevalence of *H. pylori* in patients with CD compared with 8.8% of controls without CD. As with other autoimmune conditions, the prevalence of CD is increasing (2), and 1 theory explaining this is the so-called "hygiene hypothesis," in which reduced exposure to infective antigens in childhood as Western environments become cleaner leads to an increased risk of autoimmunity (3). The authors rightly postulate reasons why this may be the case with *H. pylori* and CD with an altered T-cell response as a result of chronic *H. pylori* infection.

Although their fascinating work supports this model, there may be other models to consider. It is not clear whether patients have CD from birth, but we do know that the most common age for presentation is during the fourth or fifth decade of life (4). Could infection play another role?

Our group conducted a 2-part study that may provide evidence to support the "second hit" hypothesis. This hypothesis postulates that, in addition to a genetic predisposition, an environmental trigger is required to initiate the autoimmune process (5). In the first part of the study, we investigated 101 patients (48 men; median age, 57 years) with stool culture-proven bacterial gastroenteritis (95% *Campylobacter* species) for CD. All patients underwent tissue transglutaminase and endomysial antibody testing, and if either test was positive, we performed a small-bowel biopsy. The prevalence of CD was higher in this group of patients than in a healthy control group (2.97% vs. 1%, $P = 0.10$).

In the second part of our study, we used a validated questionnaire (6) to assess patients with CD or inflammatory bowel disease, as well as healthy controls. A total of 69 of 233 (29.6%) patients with CD and 53 of 196 (27.1%) patients with inflammatory bowel disease self-reported having a gastrointestinal infection within the 12 months prior to diagnosis. In both diseases, this rate was significantly greater than in healthy controls (15 of 219 (6.8%) patients) ($P < 0.0001$).

The role of infection in the development of CD and other autoimmune conditions is complex (3). Circumstantial evidence exists for both the protective and deleterious consequences of gastrointestinal infection, and further work is required to delineate more clearly the role of different pathogens in the development of CD.

ACKNOWLEDGMENTS

This work was funded by the Bardhan Research and Education Trust (Rotherham, United Kingdom).

Conflict of interest: none declared.

REFERENCES

1. Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with *Helicobacter pylori* colonization. *Am J Epidemiol.* 2013;178(12):1721–1730.
2. Lohi S, Mustalahti K, Kaukinen K, et al. Increasing prevalence of coeliac disease over time. *Aliment Pharmacol Ther.* 2007; 26(9):1217–1225.
3. Christen U, von Herrath MG. Infections and autoimmunity—good or bad? *J Immunol.* 2005;174(12):7481–7486.
4. Mooney PD, Leeds JS, Libzo N, et al. Case-finding for coeliac disease in secondary care: a prospective multicentre UK study. *Dig Liver Dis.* 2014;46(1):32–35.
5. Amital H, Govoni M, Maya R, et al. Role of infectious agents in systemic rheumatic diseases. *Clin Exp Rheumatol.* 2008; 26(1 suppl 48):S27–S32.
6. Sanders DS, Patel D, Stephenson TJ, et al. A primary care cross-sectional study of undiagnosed adult coeliac disease. *Eur J Gastroenterol Hepatol.* 2003;15(4):407–413.

Peter D. Mooney, Kate E. Evans, Stephen M. Barrett, Ali Arnaout, and David S. Sanders
 (e-mail: peter.mooney@sth.nhs.uk)
 Regional Gastrointestinal and Liver Unit,
 Royal Hallamshire Hospital, Sheffield, South Yorkshire,
 United Kingdom

DOI: 10.1093/aje/kwu054; Advance Access publication: April 3, 2014

THE AUTHORS REPLY

We appreciate the points made by Mooney et al. (1) regarding our study (2), and we agree that the pathogenesis of celiac disease (CD) likely involves more than 1 environmental exposure working in concert. Their findings regarding

Campylobacter in particular are consistent with a recent study of US military enlistees, in which increased rates of CD were seen after *Campylobacter* infection but not after infection with *Salmonella*, *Shigella*, or *Yersinia* (3). The

association between *Campylobacter* infection and Guillain-Barré syndrome likewise points to a parallel immune-based phenomenon (4). An increased risk of CD has also been associated with rotavirus infection (5) and antibiotic receipt (6), suggesting that there are multiple exposures through which the immune system can lose tolerance to gluten. In the data reported in the letter by Mooney et al. (1), it is uncertain whether the increased risk of developing CD was a consequence of *Campylobacter* infection itself or the antibiotics that were likely prescribed to treat this infection.

Indeed, the “2-hit hypothesis” and the “hygiene hypothesis” are not mutually exclusive. We found that *H. pylori* may be protective against the development of CD (2). Perhaps the presence of *H. pylori* prevents the “second hit,” such as an enteric viral or bacterial infection, from triggering CD. Given the rise of CD seroprevalence over the past half-century (7), at least 1 of several interacting exposures must be changing over time, and *H. pylori* has had a rapid decline during the same period as the rise in CD (8).

To develop a full model of CD pathogenesis would require longitudinal measurement of exposures, with testing for effect modification. Such a model might also incorporate information regarding infant feeding practices (such as the timing of gluten introduction and duration of breastfeeding), as well as the use of other medications that have been proposed to increase the risk of CD, such as early-life antibiotic use, acid suppression drugs, and in utero exposure to iron supplements (9). As risk factors and their interactions become better characterized, efforts can then be made for risk stratification, in which patients at increased risk of CD can be targeted for interventions to prevent its development.

ACKNOWLEDGMENTS

Conflict of interest: none declared.

REFERENCES

- Mooney PD, Evans KE, Barrett SM, et al. Re: “Decreased risk of celiac disease in patients with *Helicobacter pylori* colonization” [letter]. *Am J Epidemiol*. 2014;179(10):1275.
- Lebwohl B, Blaser MJ, Ludvigsson JF, et al. Decreased risk of celiac disease in patients with *Helicobacter pylori* colonization. *Am J Epidemiol*. 2013;178(12):1721–1730.
- Riddle MS, Murray JA, Cash BD, et al. Pathogen-specific risk of celiac disease following bacterial causes of foodborne illness: a retrospective cohort study. *Dig Dis Sci*. 2013;58(11):3242–3245.
- Poropatich KO, Walker CL, Black RE. Quantifying the association between *Campylobacter* infection and Guillain-Barré syndrome: a systematic review. *J Health Popul Nutr*. 2010;28(6):545–552.
- Stene LC, Honeyman MC, Hoffenberg EJ, et al. Rotavirus infection frequency and risk of celiac disease autoimmunity in early childhood: a longitudinal study. *Am J Gastroenterol*. 2006;101(10):2333–2340.
- Marild K, Ye W, Lebwohl B, et al. Antibiotic exposure and the development of coeliac disease: a nationwide case-control study. *BMC Gastroenterol*. 2013;13:109.
- Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. *Gastroenterology*. 2009;137(1):88–93.
- Chen Y, Blaser MJ. *Helicobacter pylori* colonization is inversely associated with childhood asthma. *J Infect Dis*. 2008;198(4):553–560.
- Lebwohl B, Ludvigsson JF, Green PH. The unfolding story of celiac disease risk factors [published online ahead of print November 7, 2013]. *Clin Gastroenterol Hepatol*. 2013. doi:10.1016/j.cgh.2013.10.031

Benjamin Lebwohl^{1,2}, Martin J. Blaser³,
Jonas F. Ludvigsson^{4,5}, Peter H. Green¹, Andrew Rundle²,
Amnon Sonnenberg⁶, and Robert M. Genta^{7,8}
(e-mail: BL114@columbia.edu)

¹ Celiac Disease Center, Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY

² Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY

³ Department of Medicine, New York University Langone Medical Center, New York, NY

⁴ Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden

⁵ Department of Pediatrics, Örebro University Hospital, Örebro, Sweden

⁶ Department of Medicine, Oregon Health and Sciences University, Portland, OR

⁷ Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX

⁸ Miraca Life Sciences Research Institute, Irving, TX

DOI: 10.1093/aje/kwu051; Advance Access publication: April 3, 2014

© The Author 2014. Published by Oxford University Press on behalf of the Johns Hopkins Bloomberg School of Public Health. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

RE: “TYPE 2 DIABETES AND THE RISK OF COLORECTAL ADENOMAS: BLACK WOMEN’S HEALTH STUDY”

Dash et al. (1) carried out a nested case-control study in 917 cases of colorectal adenoma and 2,751 controls without colorectal polyps. Contrary to their hypothesis, the authors found an unexpected inverse association between type 2 diabetes mellitus (DM) and colon adenoma risk among older African American women.

The authors suggested that the change in diet and lifestyle after diabetes diagnosis may be 1 possible explanation for the inverse association between DM and colon adenoma risk. This explanation was supported by their finding of a stronger association with increasing duration of DM. Results from other studies concur with this explanation (2, 3). The authors